Short answer:
Yes—just like many biologic medicines, Cosentyx (secukinumab) can become less effective for a patient over time. This is called secondary loss of response.
---
Why can it happen?
| Common reason | What it means | How it affects the drug |
|---------------|---------------|--------------------------|
| Immunogenicity | Your immune system creates antibodies against secukinumab. | Those antibodies can neutralize the drug or increase its clearance, so the drug level in your blood drops. |
| Trough‑level drop | The amount of drug circulating just before your next injection falls below the therapeutic range. | Lower drug levels mean less blockade of IL‑17A, so the inflammation can flare. |
| Disease evolution | The underlying inflammatory pathways can shift or intensify. | IL‑17A may become less central, or other cytokines may drive the disease. |
| Non‑adherence | Skipping doses or not following the schedule. | Obviously, no drug = no effect. |
| Drug–drug interactions | Other meds (or supplements) that speed up drug clearance. | Reduced drug exposure. |
---
What to look for
1. Clinical flare – new or worsening patches of psoriasis, joint pain, swelling, or stiffness.
2. Laboratory changes – rising inflammatory markers (CRP, ESR).
3. Patient‑reported outcomes – increased itch, pain scores, or decreased quality of life.
If you notice any of these, mention them to your prescriber promptly.
---
How it’s managed
| Step | What clinicians may do | Why it helps |
|------|------------------------|--------------|
| Check drug levels | Blood test for trough concentration of secukinumab. | Low levels confirm pharmacokinetic loss of drug. |
| Test for anti‑drug antibodies | Serum antibody assay. | Positive antibodies point to immunogenicity. |
| Adjust dose/frequency | Increase dose or shorten the interval (e.g., from 300 mg every 4 weeks to 300 mg every 2 weeks). | Raises circulating drug to a therapeutic range. |
| Switch to another biologic | TNF‑α inhibitors (adalimumab, etanercept), IL‑23 inhibitors (risankizumab, guselkumab), or JAK inhibitors (tofacitinib). | Targets a different cytokine or pathway that may now be more important. |
| Add or change concomitant meds | Topicals, oral retinoids, or methotrexate for psoriasis; NSAIDs or steroids for arthritis. | Can help bridge gaps or reduce overall inflammatory burden. |
| Review adherence | Discuss why doses are missed and find solutions (reminder apps, simplified regimens). | Ensures the drug is delivered as intended. |
Important: All changes should be made under the guidance of a rheumatologist, dermatologist, or other specialist familiar with biologic therapies.
---
Real‑world experience
- Incidence: Up to 25–30 % of patients experience a loss of response after 1–2 years.
- Timing: Some patients see a drop as early as 6–12 months; others maintain response longer.
- Switching success: About 70–80 % of patients who switch to another biologic regain control of their disease.
---
What you can do
1. Stay in touch with your healthcare provider. Let them know any new or worsening symptoms.
2. Keep a symptom diary (psoriasis severity, joint pain, itch). This data helps your doctor decide if a drug change is needed.
3. Ask about drug‑level monitoring if you’re having a flare—many clinics offer this service.
4. Follow the dosing schedule exactly; missing injections is the simplest way to lose effectiveness.
---
Bottom line
Cosentyx can lose effectiveness over time due to immune, pharmacologic, or disease‑related factors. Fortunately, there are proven ways to identify the issue and adjust therapy—either by tweaking the dose or switching to another biologic. Talk with your provider about your symptoms, and they’ll help chart the next steps.